JP2002513546A - Ｃａｅｖおよびｈｉｖ−１遺伝子エレメントから構成されるウイルスキメラ - Google Patents
Ｃａｅｖおよびｈｉｖ−１遺伝子エレメントから構成されるウイルスキメラInfo
- Publication number
- JP2002513546A JP2002513546A JP2000546798A JP2000546798A JP2002513546A JP 2002513546 A JP2002513546 A JP 2002513546A JP 2000546798 A JP2000546798 A JP 2000546798A JP 2000546798 A JP2000546798 A JP 2000546798A JP 2002513546 A JP2002513546 A JP 2002513546A
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- chiv
- caev
- virus
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 70
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title claims abstract description 13
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 title claims description 81
- 108090000623 proteins and genes Proteins 0.000 title claims description 38
- 230000002163 immunogen Effects 0.000 claims abstract description 42
- 230000028993 immune response Effects 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 33
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 29
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 29
- 229960005486 vaccine Drugs 0.000 claims abstract description 29
- 239000002157 polynucleotide Substances 0.000 claims abstract description 28
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 23
- 241000283707 Capra Species 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 5
- 206010003246 arthritis Diseases 0.000 claims abstract description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 85
- 239000002245 particle Substances 0.000 claims description 20
- 108700004025 env Genes Proteins 0.000 claims description 18
- 230000001177 retroviral effect Effects 0.000 claims description 16
- 101150030339 env gene Proteins 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 8
- 241000288906 Primates Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 5
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 26
- 230000004936 stimulating effect Effects 0.000 abstract description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 114
- 210000002966 serum Anatomy 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000003757 reverse transcription PCR Methods 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 230000010076 replication Effects 0.000 description 12
- 108700004030 rev Genes Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 208000030507 AIDS Diseases 0.000 description 11
- 241000282553 Macaca Species 0.000 description 11
- 101710149951 Protein Tat Proteins 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 101100421423 Caenorhabditis elegans spl-1 gene Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 108700004027 tat Genes Proteins 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 101150098170 tat gene Proteins 0.000 description 8
- 102100037904 CD9 antigen Human genes 0.000 description 7
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100034353 Integrase Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 102000006392 myotrophin Human genes 0.000 description 5
- 108010058605 myotrophin Proteins 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 101150098213 rev gene Proteins 0.000 description 5
- 238000002976 reverse transcriptase assay Methods 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101710177291 Gag polyprotein Proteins 0.000 description 4
- 108700010908 HIV-1 proteins Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001386 capillary affinity electrophoresis Methods 0.000 description 4
- 108091092328 cellular RNA Proteins 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101000617808 Homo sapiens Synphilin-1 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 102100021997 Synphilin-1 Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108700004028 nef Genes Proteins 0.000 description 2
- 101150023385 nef gene Proteins 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108010089520 pol Gene Products Proteins 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 101150059019 vif gene Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108700026222 vpu Genes Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 description 1
- 241000943873 Corey virus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 241000412298 Harma Species 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241001275899 Salta Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 101150050863 T gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 101710201961 Virion infectivity factor Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000047119 human OCA2 Human genes 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 101150090490 vpu gene Proteins 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8365298P | 1998-04-30 | 1998-04-30 | |
| US60/083,652 | 1998-04-30 | ||
| US09/302,171 | 1999-04-29 | ||
| US09/302,171 US6602505B2 (en) | 1998-04-30 | 1999-04-29 | Viral chimeras comprised of CAEV and HIV-1 genetic elements |
| PCT/US1999/006556 WO1999056774A1 (en) | 1998-04-30 | 1999-04-30 | Viral chimeras comprised of caev and hiv-1 genetic elements |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002513546A true JP2002513546A (ja) | 2002-05-14 |
| JP2002513546A5 JP2002513546A5 (enExample) | 2006-06-15 |
Family
ID=26769556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000546798A Pending JP2002513546A (ja) | 1998-04-30 | 1999-04-30 | Ｃａｅｖおよびｈｉｖ−１遺伝子エレメントから構成されるウイルスキメラ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6602505B2 (enExample) |
| EP (1) | EP1073461B1 (enExample) |
| JP (1) | JP2002513546A (enExample) |
| KR (1) | KR20010074495A (enExample) |
| CN (1) | CN100346827C (enExample) |
| AT (1) | ATE284709T1 (enExample) |
| AU (1) | AU766264B2 (enExample) |
| CA (1) | CA2330618C (enExample) |
| DE (1) | DE69922642T2 (enExample) |
| IL (2) | IL139360A0 (enExample) |
| NZ (1) | NZ507942A (enExample) |
| WO (1) | WO1999056774A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014527812A (ja) * | 2011-09-12 | 2014-10-23 | サントル ナスィオナル ド ラ ルシェルシュ スィアンティフィク（セ．エン．エル．エス．） | Ｈｉｖ−１に対する革新的ワクチンとしての非組み込み型キメラレンチウイルスゲノム |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361784B1 (en) * | 2000-09-29 | 2002-03-26 | The Procter & Gamble Company | Soft, flexible disposable wipe with embossing |
| WO2013126469A1 (en) * | 2012-02-21 | 2013-08-29 | Immunogenetix Therapeutics, Inc. | Chimeric dna vaccine compositions and methods of use |
| RU2017126206A (ru) * | 2014-12-23 | 2019-01-25 | Маргарет Анне БРИМБЛЕ | Аминокислотные и пептидные конъюгаты и направления их использования |
| AU2017223267B2 (en) | 2016-02-26 | 2021-07-22 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5142025A (en) | 1986-08-01 | 1992-08-25 | Repligen Corporation | Recombinant HTLV-III proteins and uses thereof |
| US5256767A (en) | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5851813A (en) | 1990-07-12 | 1998-12-22 | President And Fellows Of Harvard College | Primate lentivirus antigenic compositions |
| US5714374A (en) | 1990-09-12 | 1998-02-03 | Rutgers University | Chimeric rhinoviruses |
| US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
| US5561064A (en) | 1994-02-01 | 1996-10-01 | Vical Incorporated | Production of pharmaceutical-grade plasmid DNA |
| FR2721618B1 (fr) | 1994-06-28 | 1996-09-13 | Centre Nat Rech Scient | Fragments d'acide nucléique et fragments peptidiques correspondants issus du génome du virus de l'arthrite et de l'encéphalite caprine (VAEC) et leurs applications. |
| US5955342A (en) | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| FR2732346B1 (fr) | 1995-03-27 | 1997-05-30 | Centre Nat Rech Scient | Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications |
| DE69707680T2 (de) | 1996-03-15 | 2002-07-11 | University Of Southern California, Los Angeles | Caprin arthritis-enzephalitis virus enthaltende vakzine und verwendung zur immunschutz gegen hiv-1 infektion |
| US5770357A (en) | 1996-03-15 | 1998-06-23 | Univ Southern California | Method of diagnosing caprine arthritis-encephalitis virus infection |
| EP1012236A1 (en) * | 1997-08-15 | 2000-06-28 | Rubicon Laboratory Inc. | Retrovirus and viral vectors |
-
1999
- 1999-04-29 US US09/302,171 patent/US6602505B2/en not_active Expired - Lifetime
- 1999-04-30 AT AT99919756T patent/ATE284709T1/de not_active IP Right Cessation
- 1999-04-30 AU AU37406/99A patent/AU766264B2/en not_active Ceased
- 1999-04-30 DE DE69922642T patent/DE69922642T2/de not_active Expired - Lifetime
- 1999-04-30 NZ NZ507942A patent/NZ507942A/xx not_active IP Right Cessation
- 1999-04-30 KR KR1020007012062A patent/KR20010074495A/ko not_active Withdrawn
- 1999-04-30 IL IL13936099A patent/IL139360A0/xx active IP Right Grant
- 1999-04-30 WO PCT/US1999/006556 patent/WO1999056774A1/en not_active Ceased
- 1999-04-30 JP JP2000546798A patent/JP2002513546A/ja active Pending
- 1999-04-30 EP EP99919756A patent/EP1073461B1/en not_active Expired - Lifetime
- 1999-04-30 CA CA2330618A patent/CA2330618C/en not_active Expired - Fee Related
- 1999-04-30 CN CNB99807912XA patent/CN100346827C/zh not_active Expired - Fee Related
-
2000
- 2000-10-30 IL IL139360A patent/IL139360A/en not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| JPN5001012304, ＬＵＣＩＷ, ＰＲＯＣ ＮＡＴＬ ＡＣＡＤ ＳＣＩ ＵＳＡ, 19950801, Ｖ９２, Ｐ７４９０−７４９４ * |
| JPN6008065688, Ｔｒｅｎｄｓ Ｂｉｏｔｅｃｈｎｏｌ．, 1995, Ｖｏｌ．１３， Ｎｏ．４, １４２−１５０ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014527812A (ja) * | 2011-09-12 | 2014-10-23 | サントル ナスィオナル ド ラ ルシェルシュ スィアンティフィク（セ．エン．エル．エス．） | Ｈｉｖ−１に対する革新的ワクチンとしての非組み込み型キメラレンチウイルスゲノム |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE284709T1 (de) | 2005-01-15 |
| US20010039669A1 (en) | 2001-11-08 |
| KR20010074495A (ko) | 2001-08-04 |
| EP1073461A1 (en) | 2001-02-07 |
| NZ507942A (en) | 2003-06-30 |
| EP1073461B1 (en) | 2004-12-15 |
| WO1999056774A1 (en) | 1999-11-11 |
| CA2330618A1 (en) | 1999-11-11 |
| CN1311689A (zh) | 2001-09-05 |
| DE69922642D1 (de) | 2005-01-20 |
| US6602505B2 (en) | 2003-08-05 |
| IL139360A0 (en) | 2001-11-25 |
| AU766264B2 (en) | 2003-10-09 |
| EP1073461A4 (en) | 2002-03-20 |
| DE69922642T2 (de) | 2005-12-22 |
| CA2330618C (en) | 2012-07-03 |
| IL139360A (en) | 2007-07-24 |
| AU3740699A (en) | 1999-11-23 |
| CN100346827C (zh) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12370253B2 (en) | Pre-immunization and immunotherapy | |
| US12090200B2 (en) | Methods of producing cells resistant to HIV infection | |
| US5851813A (en) | Primate lentivirus antigenic compositions | |
| JP2000516445A (ja) | 合成遺伝子を含むワクチン | |
| KR19990087126A (ko) | 합성 사람 면역결핍 바이러스 유전자 | |
| PT778888E (pt) | Particulas semelhantes a retrovírus não infecciosas antigenicamente marcadas. | |
| JPH08500965A (ja) | ハイブリッドウイルス発現ベクター，その使用および新規アッセイ | |
| BR112019014082A2 (pt) | Imunoterapia para hiv sem etapa de pré-imunização | |
| CN103189506A (zh) | 包含痘苗病毒载体和仙台病毒载体的初免-加强疫苗用病毒载体 | |
| EP0491930B1 (en) | Primate lentivirus vaccines | |
| Narayan et al. | Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques | |
| KR100347220B1 (ko) | 재조합아데노바이러스hiv백신 | |
| JP4477770B2 (ja) | ネコ免疫不全ウイルスのｅｎｖ遺伝子に由来するペプチド、およびその使用 | |
| JP2002513546A (ja) | Ｃａｅｖおよびｈｉｖ−１遺伝子エレメントから構成されるウイルスキメラ | |
| JP2003535577A (ja) | 免疫不全ウイルス用生ウイルスワクチンとしての組換えラブドウイルス | |
| JPH08501452A (ja) | Ｆｅｌｖ及び／又はｆｉｖに対する組換レトロウィルスベクター | |
| WO2008070385A2 (en) | Uses of a murine model of hiv-1 infection | |
| ZA200006314B (en) | Viral chimeras comprised of CAEV and HIV-1 genetic elements. | |
| US5753490A (en) | Recombinant HIV and modified packaging cells and method for treating acquired immune deficiency syndrome | |
| MXPA00010701A (es) | Quimeras virales comprendidas por elementos geneticos de hiv-1 y caev | |
| US6063374A (en) | Recombinant HIV and modified packaging cells and method for using | |
| US20030068332A1 (en) | Replication-competent recombinant virus and methods of use thereof | |
| Whitney | Characterization and functional analysis of the SIV untranslated region | |
| WO2002098457A2 (en) | Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060418 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060418 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100326 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100402 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100426 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100507 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100527 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100603 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100831 |